The DoDo experience: an alternative antiretroviral 2-drug regimen of doravirine and dolutegravir.

"Declarations Conflict of interestS.S.: Advisory board honorarium from MSD. Travel/conference support from Gilead Sciences. E.W.: Honoraria for lectures, advisory boards or registration/travel expenses from AbbVie, Biogen, Gilead Sciences, Janssen-Cilag, MSD, ViiV Healthcare. Involved in (research) projects supported by AbbVie, Gilead Sciences, Janssen-Cilag, MSD, ViiV Healthcare. C.B.: Honoraria for lectures and/or consultancies from AbbVie, Gilead Sciences, Janssen, MSD, ViiV. Funding from DFG, Dt. Leberstiftung, DZIF, Hector Stiftung, NEAT ID. J.Roc.: Honoraria for lectures and/or consultancies from AbbVie, Boehringer, Galapagos, Gilead Sciences, Janssen, MSD, ViiV. Funding from DFG, Dt. Leberstiftung, DZIF, Hector Stiftung, NEAT ID. S.Scho.: Speakers’ honoraria from ViiV, Gilead Sciences, Janssen, Cepheid. Honoraria for consultancies from Gilead Sciences, ViiV. Travel/conference support from Gilead Sciences, Janssen, ViiV. Funding from GSK, ViiV, Gilead Sciences, INSTO, Heidelberg Therapeutics. S.Schn.: Speakers’ honoraria from ViiV, MSD, INSTO. Honoraria for consultancies from ViiV. Travel/conference support from Gilead Sciences, Janssen, ViiV. Funding from GSK, ViiV, Gilead Sciences, Heidelberg Therapeutics. J.Roi.: Speakers’ honoraria from Gilead Sciences. Funding from DZIF, Else Kröner-Fresenius-Stiftung U.S.: Speakers’ honoraria from Gilead Sciences, ViiV, Janssen Cilag. Honoraria for consultancies from Gilead Sciences and ViiV. Travel/conference support from Gilead, ViiV. Poster award from Hector Stiftung. All other authors: no perceived potential conflict of interest. Ethics approvalThe work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans. The study protocol has been approved by the Ethics Committee at Ludwig-Maximilians-Universität München (project number 21-0044) and all ethics committees responsible for the specific study sites. The study has been submitted to the German Registry for Clinical Studies (DRKS) with the ID 00030471. Written informed consent was obtained from all participants before inclusion into the study. Conflict of interest S.S.: Advisory board honorarium from MSD. Travel/conference support from Gilead Sciences. E.W.: Honoraria for lectures, advisory boards or registration/travel expenses from AbbVie, Biogen, Gilead Sciences, Janssen-Cilag, MSD, ViiV Healthcare. Involved in (research) projects supported by AbbVie, Gilead Sciences, Janssen-Cilag, MSD, ViiV Healthcare. C.B.: Honoraria for lectures and/or consultancies from AbbVie, Gilead Sciences, Janssen, MSD, ViiV. Funding from DFG, Dt. Leberstiftung, DZIF, Hector Stiftung, NEAT ID. J.Roc.: Honoraria for lectures and/or consultancies from AbbVie, Boehringer, Galapagos, Gilead Sciences, Janssen, MSD, ViiV. Funding from DFG, Dt. Leberstiftung, DZIF, Hector Stiftung, NEAT ID. S.Scho.: Speakers’ honoraria from ViiV, Gilead Sciences, Janssen, Cepheid. Honoraria for consultancies from Gilead Sciences, ViiV. Travel/conference support from Gilead Sciences, Janssen, ViiV. Funding from GSK, ViiV, Gilead Sciences, INSTO, Heidelberg Therapeutics. S.Schn.: Speakers’ honoraria from ViiV, MSD, INSTO. Honoraria for consultancies from ViiV. Travel/conference support from Gilead Sciences, Janssen, ViiV. Funding from GSK, ViiV, Gilead Sciences, Heidelberg Therapeutics. J.Roi.: Speakers’ honoraria from Gilead Sciences. Funding from DZIF, Else Kröner-Fresenius-Stiftung U.S.: Speakers’ honoraria from Gilead Sciences, ViiV, Janssen Cilag. Honoraria for consultancies from Gilead Sciences and ViiV. Travel/conference support from Gilead, ViiV. Poster award from Hector Stiftung. All other authors: no perceived potential conflict of interest."

"Funding Open Access funding enabled and organized by Projekt DEAL. This research received the DÖAK 2021 poster award by the H.W. & J. Hector Foundation. No other grant/funding from agencies in the public, commercial, or not-for-profit sectors was available."

"Declarations: Conflict of interestS.S.: Advisory board honorarium from MSD. Travel/conference support from Gilead Sciences. E.W.: Honoraria for lectures, advisory boards or registration/travel expenses from AbbVie, Biogen, Gilead Sciences, Janssen-Cilag, MSD, ViiV Healthcare. Involved in (research) projects supported by AbbVie, Gilead Sciences, Janssen-Cilag, MSD, ViiV Healthcare. C.B.: Honoraria for lectures and/or consultancies from AbbVie, Gilead Sciences, Janssen, MSD, ViiV. Funding from DFG, Dt. Leberstiftung, DZIF, Hector Stiftung, NEAT ID. J.Roc.: Honoraria for lectures and/or consultancies from AbbVie, Boehringer, Galapagos, Gilead Sciences, Janssen, MSD, ViiV. Funding from DFG, Dt. Leberstiftung, DZIF, Hector Stiftung, NEAT ID. S.Scho.: Speakers’ honoraria from ViiV, Gilead Sciences, Janssen, Cepheid. Honoraria for consultancies from Gilead Sciences, ViiV. Travel/conference support from Gilead Sciences, Janssen, ViiV. Funding from GSK, ViiV, Gilead Sciences, INSTO, Heidelberg Therapeutics. S.Schn.: Speakers’ honoraria from ViiV, MSD, INSTO. Honoraria for consultancies from ViiV. Travel/conference support from Gilead Sciences, Janssen, ViiV. Funding from GSK, ViiV, Gilead Sciences, Heidelberg Therapeutics. J.Roi.: Speakers’ honoraria from Gilead Sciences. Funding from DZIF, Else Kröner-Fresenius-Stiftung U.S.: Speakers’ honoraria from Gilead Sciences, ViiV, Janssen Cilag. Honoraria for consultancies from Gilead Sciences and ViiV. Travel/conference support from Gilead, ViiV. Poster award from Hector Stiftung. All other authors: no perceived potential conflict of interest.: Ethics approvalThe work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans. The study protocol has been approved by the Ethics Committee at Ludwig-Maximilians-Universität München (project number 21-0044) and all ethics committees responsible for the specific study sites. The study has been submitted to the German Registry for Clinical Studies (DRKS) with the ID 00030471. Written informed consent was obtained from all participants before inclusion into the study. Ethics approval: The work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans. The study protocol has been approved by the Ethics Committee at Ludwig-Maximilians-Universität München (project number 21-0044) and all ethics committees responsible for the specific study sites. The study has been submitted to the German Registry for Clinical Studies (DRKS) with the ID 00030471. Written informed consent was obtained from all participants before inclusion into the study."